JP2017536558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536558A5 JP2017536558A5 JP2017546035A JP2017546035A JP2017536558A5 JP 2017536558 A5 JP2017536558 A5 JP 2017536558A5 JP 2017546035 A JP2017546035 A JP 2017546035A JP 2017546035 A JP2017546035 A JP 2017546035A JP 2017536558 A5 JP2017536558 A5 JP 2017536558A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- subject
- egf
- mcp1
- ngal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 239000000090 biomarker Substances 0.000 claims 11
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 7
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 7
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 7
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims 5
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 5
- 229940116977 epidermal growth factor Drugs 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 3
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims 2
- 102000013382 Gelatinases Human genes 0.000 claims 2
- 108010026132 Gelatinases Proteins 0.000 claims 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 2
- 102000019298 Lipocalin Human genes 0.000 claims 2
- 108050006654 Lipocalin Proteins 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 108091022862 fatty acid binding Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 1
- 102000012192 Cystatin C Human genes 0.000 claims 1
- 108010061642 Cystatin C Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 claims 1
- 108010051335 Lipocalin-2 Proteins 0.000 claims 1
- 102000004264 Osteopontin Human genes 0.000 claims 1
- 108010081689 Osteopontin Proteins 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 102100040613 Uromodulin Human genes 0.000 claims 1
- 108010027007 Uromodulin Proteins 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306879 | 2014-11-25 | ||
| EP14306879.9 | 2014-11-25 | ||
| PCT/EP2015/077504 WO2016083374A1 (en) | 2014-11-25 | 2015-11-24 | Biomarkers of fast progression of chronic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536558A JP2017536558A (ja) | 2017-12-07 |
| JP2017536558A5 true JP2017536558A5 (enExample) | 2018-12-27 |
| JP6753861B2 JP6753861B2 (ja) | 2020-09-09 |
Family
ID=52002880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546035A Active JP6753861B2 (ja) | 2014-11-25 | 2015-11-24 | 慢性腎疾患の急速進行のバイオマーカー |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20170328914A1 (enExample) |
| EP (1) | EP3224625B1 (enExample) |
| JP (1) | JP6753861B2 (enExample) |
| CN (1) | CN107003320B (enExample) |
| WO (1) | WO2016083374A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016083374A1 (en) | 2014-11-25 | 2016-06-02 | F. Hoffmann-La Roche Ag | Biomarkers of fast progression of chronic kidney disease |
| US12057228B1 (en) | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| US11026625B2 (en) * | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| WO2019217916A1 (en) * | 2018-05-10 | 2019-11-14 | The Methodist Hospital | Methods for prognosis and management of disease |
| ES2745352B2 (es) * | 2018-08-28 | 2023-08-10 | Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz | GDF15 en orina como biomarcador de enfermedad renal crónica |
| US20200116740A1 (en) * | 2018-10-11 | 2020-04-16 | Northwestern University | Discovery and validation of an early post-transplant biomarker predictive of chronic kidney disease in liver transplant recipients |
| CN113667713A (zh) * | 2020-05-14 | 2021-11-19 | 深圳市长卿医学研究院 | 一种肾功能损害风险降低的方法及应用 |
| US20220093261A1 (en) * | 2020-09-23 | 2022-03-24 | Baxter International Inc. | Chronic kidney disease (ckd) machine learning prediction system, methods, and apparatus |
| WO2022217283A1 (en) * | 2021-04-08 | 2022-10-13 | Joslin Diabetes Center, Inc. | Methods of diagnosing and predicting renal decline |
| CN116042809B (zh) * | 2022-12-12 | 2025-07-15 | 山西省人民医院 | X连锁凋亡抑制蛋白在慢性肾脏病诊断中的应用 |
| CN118707104A (zh) * | 2024-05-08 | 2024-09-27 | 杭州珞米医疗科技有限公司 | 蛋白标志物联合用于制备诊断区分糖尿病肾病进展者与非进展者的试剂盒的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2519722C2 (ru) * | 2008-11-21 | 2014-06-20 | Пхадиа Аб | Способы, устройства и наборы для детекции или мониторинга острого повреждения почек |
| ES2528799T3 (es) * | 2008-11-22 | 2015-02-12 | Astute Medical, Inc. | Métodos para el pronóstico de insuficiencia renal aguda |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| CN103080743B (zh) | 2010-06-23 | 2015-07-22 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| US20140079769A1 (en) * | 2010-10-01 | 2014-03-20 | Fabiola Terzi | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| CN102854306B (zh) * | 2011-12-23 | 2013-08-07 | 中国人民解放军第三〇九医院 | 用于预警肾移植后排斥反应的试剂盒及其使用方法 |
| WO2016083374A1 (en) | 2014-11-25 | 2016-06-02 | F. Hoffmann-La Roche Ag | Biomarkers of fast progression of chronic kidney disease |
| US20200116740A1 (en) | 2018-10-11 | 2020-04-16 | Northwestern University | Discovery and validation of an early post-transplant biomarker predictive of chronic kidney disease in liver transplant recipients |
-
2015
- 2015-11-24 WO PCT/EP2015/077504 patent/WO2016083374A1/en not_active Ceased
- 2015-11-24 EP EP15801747.5A patent/EP3224625B1/en active Active
- 2015-11-24 JP JP2017546035A patent/JP6753861B2/ja active Active
- 2015-11-24 CN CN201580062658.8A patent/CN107003320B/zh active Active
-
2017
- 2017-05-25 US US15/604,888 patent/US20170328914A1/en not_active Abandoned
-
2019
- 2019-08-20 US US16/546,101 patent/US20200096523A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,406 patent/US12203943B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536558A5 (enExample) | ||
| Lurier et al. | Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing | |
| Rodrigues-Amorim et al. | Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship | |
| Famulski et al. | Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts | |
| Aguado et al. | Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation | |
| Kahli et al. | Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass | |
| Jonigk et al. | Molecular profiling in lung biopsies of human pulmonary allografts to predict chronic lung allograft dysfunction | |
| Madsen et al. | Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis | |
| Ju et al. | Genomic biomarkers for chronic kidney disease | |
| JP2016513253A (ja) | 急性呼吸促迫症候群（ａｒｄｓ）関連バイオマーカーを測定する方法、患者におけるａｒｄｓの進行および治療をモニターする方法 | |
| Chou et al. | Leptospirosis kidney disease: Evolution from acute to chronic kidney disease | |
| JP2008537474A5 (enExample) | ||
| JP2016539349A5 (enExample) | ||
| JP2021523744A (ja) | 脳卒中の血液バイオマーカー | |
| Kabeerdoss et al. | High expression of pro-inflammatory cytokine genes IL-1β and IL-1R2 upon TLR4 activation in Takayasu arteritis | |
| JP2020512549A5 (enExample) | ||
| Reich et al. | Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritis | |
| Mourino-Alvarez et al. | Proteomic characterization of EPCs and CECs “in vivo” from acute coronary syndrome patients and control subjects | |
| US20200338039A1 (en) | Methods and materials for assessing biological age and slowing the progress of excessive biological aging | |
| Zheng et al. | Targeted bisulfite resequencing of differentially methylated cytosines in pre-eclampsia reveals a skewed dynamic balance in the DNA methylation of enhancers | |
| GB2582074A (en) | Methods and systems for detecting tissue conditions | |
| KR102681869B1 (ko) | 줄기 세포를 모니터링하기 위한 조성물, 키트, 및 이를 이용한 줄기 세포를 모니터링하는 방법 | |
| US20210087634A1 (en) | Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna | |
| FR2941239B1 (fr) | Procede pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient presentant une reponse systemique inflammatoire associee ou non a une infection. | |
| JP6760948B2 (ja) | 慢性弁膜疾患を診断するための方法 |